<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32326899</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-2407</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMC cancer</Title>
          <ISOAbbreviation>BMC Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.</ArticleTitle>
        <Pagination>
          <StartPage>349</StartPage>
          <MedlinePgn>349</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">349</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-020-06820-6</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Testicular germ cell tumours (TGCTs) are characterised by an overall high cisplatin-sensitivity which has been linked to their continued expression of pluripotency factors. Recently, the Nodal signalling pathway has been implicated in the regulation of pluripotency factor expression in fetal germ cells, and the pathway could therefore also be involved in regulating expression of pluripotency factors in malignant germ cells, and hence cisplatin-sensitivity in TGCTs.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We used in vitro culture of the TGCT-derived cell line NTera2, ex vivo tissue culture of primary TGCT specimens and xenografting of NTera2 cells into nude mice in order to investigate the consequences of manipulating Nodal and Activin signalling on pluripotency factor expression, apoptosis, proliferation and cisplatin-sensitivity.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">The Nodal signalling factors were markedly expressed concomitantly with the pluripotency factor OCT4 in GCNIS cells, seminomas and embryonal carcinomas. Despite this, inhibition of Nodal and Activin signalling either alone or simultaneously did not affect proliferation or apoptosis in malignant germ cells in vitro or ex vivo. Interestingly, inhibition of Nodal signalling in vitro reduced the expression of pluripotency factors and Nodal pathway genes, while stimulation of the pathway increased their expression. However, cisplatin-sensitivity was not affected following pharmacological inhibition of Nodal/Activin signalling or siRNA-mediated knockdown of the obligate co-receptor CRIPTO in NTera2 cells in vitro or in a xenograft model.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that the Nodal signalling pathway may be involved in regulating pluripotency factor expression in malignant germ cells, but manipulation of the pathway does not appear to affect cisplatin-sensitivity or tumour cell proliferation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Harpelunde Poulsen</LastName>
            <ForeName>K</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nielsen</LastName>
            <ForeName>J E</ForeName>
            <Initials>JE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grønkær Toft</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Pathology Department, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joensen</LastName>
            <ForeName>U N</ForeName>
            <Initials>UN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, 2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rasmussen</LastName>
            <ForeName>L J</ForeName>
            <Initials>LJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Molecular Medicine, Center for Healthy Aging, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blomberg Jensen</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitchell</LastName>
            <ForeName>R T</ForeName>
            <Initials>RT</Initials>
            <AffiliationInfo>
              <Affiliation>MRC Centre for Reproductive Health, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juul</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rajpert-De Meyts</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jørgensen</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Growth and Reproduction, Copenhagen University Hospital (Rigshospitalet), Blegdamsvej 9, DK-2100, Copenhagen, Denmark. aj@rh.regionh.dk.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>International Research and Research Training Centre in Endocrine Disruption of Male Reproduction and Child Health (EDMaRC), Blegdamsvej 9, Copenhagen, Denmark. aj@rh.regionh.dk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMC Cancer</MedlineTA>
        <NlmUniqueID>100967800</NlmUniqueID>
        <ISSNLinking>1471-2407</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>Q20Q21Q62J</RegistryNumber>
          <NameOfSubstance UI="D002945">Cisplatin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C563236">Testicular Germ Cell Tumor</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002945" MajorTopicYN="N">Cisplatin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009373" MajorTopicYN="N">Neoplasms, Germ Cell and Embryonal</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D039904" MajorTopicYN="N">Pluripotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013736" MajorTopicYN="N">Testicular Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cisplatin-sensitivity</Keyword>
        <Keyword MajorTopicYN="N">Expression of pluripotency factors</Keyword>
        <Keyword MajorTopicYN="N">GCNIS</Keyword>
        <Keyword MajorTopicYN="N">Nodal and Activin signalling</Keyword>
        <Keyword MajorTopicYN="N">Testicular cancer</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32326899</ArticleId>
        <ArticleId IdType="pmc">PMC7181506</ArticleId>
        <ArticleId IdType="doi">10.1186/s12885-020-06820-6</ArticleId>
        <ArticleId IdType="pii">10.1186/s12885-020-06820-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Skakkebaek NE. Possible carcinoma-in-situ of the testis. Lancet (London, England) 1972;2:516–517. doi: 10.1016/s0140-6736(72)91909-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(72)91909-5</ArticleId>
            <ArticleId IdType="pubmed">4115573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl. 1987;10:19–28. doi: 10.1111/j.1365-2605.1987.tb00161.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2605.1987.tb00161.x</ArticleId>
            <ArticleId IdType="pubmed">3034791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update. 2006;12:303–23. 10.1093/humupd/dmk006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16540528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulbright TM, Amin MB, Balzer B, Berney DM, Epstein JI, Guo C, Idrees MT, Looijenga LHJ, Paner G, Rajpert-De Meyts E, Skakkebaek NE, Tickoo SK, Yilmaz A, and Oosterhuis JW, in WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn., ed. by H. Moch, P.A. Humphrey, T.M. Ulbright. Germ cell tumours (IARC Press, Lyon, 2016), 189–226.</Citation>
        </Reference>
        <Reference>
          <Citation>Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MAS, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762–1774. doi: 10.1016/S0140-6736(15)00991-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(15)00991-5</ArticleId>
            <ArticleId IdType="pubmed">26651223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacobsen C, Honecker F. Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology. 2015;3:111–121. doi: 10.1111/andr.299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/andr.299</ArticleId>
            <ArticleId IdType="pubmed">25546083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R, Fazal Z, Freemantle SJ, Spinella MJ. Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors. Cancer Drug Resist (Alhambra, Calif.) 2019;2:580–594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6752046</ArticleId>
            <ArticleId IdType="pubmed">31538140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oosterhuis JW, Looijenga LHJ. Human germ cell tumours from a developmental perspective. Nat Rev Cancer. 2019;19:522–537. doi: 10.1038/s41568-019-0178-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0178-9</ArticleId>
            <ArticleId IdType="pubmed">31413324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumor Biol. 2006;27:71–83. doi: 10.1159/000092324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000092324</ArticleId>
            <ArticleId IdType="pubmed">16557044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen A, Blomberg Jensen M, Nielsen JE, Juul A, Rajpert-De Meyts E. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol. 2013;136:238–46. 10.1016/j.jsbmb.2012.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23098692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abada PB, Howell SB. Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. PLoS One. 2014;9:e87444. doi: 10.1371/journal.pone.0087444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0087444</ArticleId>
            <ArticleId IdType="pmc">PMC3903721</ArticleId>
            <ArticleId IdType="pubmed">24475288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudolph C, Melau C, Nielsen JE, Vile Jensen K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ, Jørgensen A. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. Cell Oncol. 2017;40:341–355. doi: 10.1007/s13402-017-0326-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13402-017-0326-8</ArticleId>
            <ArticleId IdType="pubmed">28536927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672–684. doi: 10.1001/jama.299.6.672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.299.6.672</ArticleId>
            <ArticleId IdType="pubmed">18270356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baldassarre G, Romano A, Armenante F, Rambaldi M, Paoletti I, Sandomenico C, Pepe S, Staibano S, Salvatore G, De Rosa G, Persico MG, Viglietto G. Expression of teratocarcinoma-derived growth factor-1 (TDGF-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2 / D1. Oncogene. 1997;15:927–936. doi: 10.1038/sj.onc.1201260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1201260</ArticleId>
            <ArticleId IdType="pubmed">9285688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe K, Meyer MJ, Strizzi L, Lee JM, Gonzales M, Bianco C, Nagaoka T, Farid SS, Margaryan N, Hendrix MJC, Vonderhaar BK, Salomon DS. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human Embryonal carcinoma cells. Stem Cells. 2010;28:1303–1314. doi: 10.1002/stem.463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.463</ArticleId>
            <ArticleId IdType="pmc">PMC3069615</ArticleId>
            <ArticleId IdType="pubmed">20549704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiller CM, Feng CW, Jackson A, Gillis AJM, Rolland AD, Looijenga LHJ, Koopman P, Bowles J. Endogenous nodal signaling regulates germ cell potency during mammalian testis development. Development. 2012;139:4123–4132. doi: 10.1242/dev.083006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.083006</ArticleId>
            <ArticleId IdType="pubmed">23034635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiller CM, Gillis AJM, Burnet G, Stoop H, Koopman P, Bowles J, Looijenga LHJ. Cripto: Expression, epigenetic regulation and potential diagnostic use in testicular germ cell tumors. Mol Oncol. 2015;30:1–12. doi: 10.1016/j.molonc.2015.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molonc.2015.11.003</ArticleId>
            <ArticleId IdType="pmc">PMC5423140</ArticleId>
            <ArticleId IdType="pubmed">26654129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nettersheim D, Jostes S, Sharma R, Schneider S, Hofmann A, Ferreira HJ, Hoffmann P, Kristiansen G, Esteller MB, Schorle H. BMP inhibition in seminomas initiates Acquisition of Pluripotency via NODAL signaling resulting in reprogramming to an Embryonal carcinoma. PLoS Genet. 2015;11:1–26. doi: 10.1371/journal.pgen.1005415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1005415</ArticleId>
            <ArticleId IdType="pmc">PMC4520454</ArticleId>
            <ArticleId IdType="pubmed">26226633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen A, Macdonald J, Nielsen JE, Kilcoyne KR, Perlman S, Lundvall L, Langhoff Thuesen L, Juul Hare K, Frederiksen H, Andersson AM, Skakkebæk NE, Juul AR, Sharpe M, Rajpert-De Meyts E, Mitchell RT. Nodal Signaling Regulates Germ Cell Development and Establishment of Seminiferous Cords in the Human Fetal Testis. Cell Reports. 2018;25:1924–1937.e4. doi: 10.1016/j.celrep.2018.10.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.10.064</ArticleId>
            <ArticleId IdType="pubmed">30428358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harpelunde Poulsen K, Jorgensen A. Role of Nodal signalling in testis development and initiation of testicular cancer. Reproduction (Cambridge, England) 2019;158:R67–R77. doi: 10.1530/REP-18-0641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/REP-18-0641</ArticleId>
            <ArticleId IdType="pubmed">30999282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng SK, F., Olale BAH, Schier AF. Lefty blocks a subset of TGFβ signals by antagonizing EGF-CFC coreceptors. PLoS Biology. 2004;2:e30. doi: 10.1371/journal.pbio.0020030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.0020030</ArticleId>
            <ArticleId IdType="pmc">PMC340941</ArticleId>
            <ArticleId IdType="pubmed">14966532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, Nickoloff BJ, Topczewski J, Hendrix MJC. Embryonic and tumorigenic pathways converge via nodal signaling: role in melanoma aggressiveness. Nat Med. 2006;12:925–932. doi: 10.1038/nm1448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1448</ArticleId>
            <ArticleId IdType="pubmed">16892036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR, Lai J, BioResource APC, Postovit LM, Clements JA, Hendrix MJC. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate. 2011;71:1198–1209. doi: 10.1002/pros.21335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pros.21335</ArticleId>
            <ArticleId IdType="pmc">PMC3234312</ArticleId>
            <ArticleId IdType="pubmed">21656830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonardo E, et al.  Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433–446. doi: 10.1016/j.stem.2011.10.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stem.2011.10.001</ArticleId>
            <ArticleId IdType="pubmed">22056140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJC. Potential for the embryonic morphogen nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012;14:R75. doi: 10.1186/bcr3185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr3185</ArticleId>
            <ArticleId IdType="pmc">PMC3446338</ArticleId>
            <ArticleId IdType="pubmed">22577960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong W, Sun B, Sun H, Zhao X, Zhang D, Liu T, Zhao N, Gu Q, Dong X and Liu F. Nodal signaling activates the Smad2/3 pathway to regulate stem cell-like properties in breast cancer cells. Am J Cancer Res 2017;7:503–517. PMID: 28401007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5385639</ArticleId>
            <ArticleId IdType="pubmed">28401007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajpert-De Meyts E, Nielsen JE, Skakkebæk NE, Almstrup K. Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs. Folia Histochem Cytobiol. 2015;53(3):177–188. doi: 10.5603/FHC.a2015.0020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5603/FHC.a2015.0020</ArticleId>
            <ArticleId IdType="pubmed">26306513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen A, Nielsen JE, Blomberg Jensen M, Græm N, Rajpert-De Meyts E. Analysis of meiosis regulators in human gonads: a sexually dimorphic spatio-temporal expression pattern suggests involvement of DMRT1 in meiotic entry. Mol Hum Reprod. 2012;18:523–34. 10.1093/molehr/gas030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22899867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svingen T, Jørgensen A, Rajpert-De Meyts E. Validation of endogenous normalizing genes for expression analyses in adult human testis and germ cell neoplasms. Mol Hum Reprod. 2014;20:709–18. 10.1093/molehr/gau030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24743772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method, Methods (San Diego, Calif.). 2001;25:402–8. 10.1006/meth.2001.1262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, Dracopoli NC, Fogh J. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2: differentiation in vivo and in vitro. Lab Investig. 1984;50:147–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6694356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I Activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65–74. doi: 10.1124/mol.62.1.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.62.1.65</ArticleId>
            <ArticleId IdType="pubmed">12065756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jørgensen A, Young J, Nielsen JE, Joensen UN, Toft BG, Rajpert-De Meyts E, Loveland KL. Hanging drop cultures of human testis and testis cancer samples: a model used to investigate activin treatment effects in a preserved niche. Br J Cancer. 2014;110:2604–2614. doi: 10.1038/bjc.2014.160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2014.160</ArticleId>
            <ArticleId IdType="pmc">PMC4021512</ArticleId>
            <ArticleId IdType="pubmed">24781282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blomberg Jensen M, Jørgensen A, Nielsen JE, Steinmeyer A, Leffers H, Juul A, Rajpert-De Meyts E. Vitamin D Metabolism and effects on Pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo. Neoplasia. 2012;14:952–963. doi: 10.1593/neo.121164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1593/neo.121164</ArticleId>
            <ArticleId IdType="pmc">PMC3479852</ArticleId>
            <ArticleId IdType="pubmed">23097629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Q, Kanata K, Saba R, Deng CX, Hamada H, Saga Y. Nodal/activin signaling promotes male germ cell fate and suppresses female programming in somatic cells. Development. 2013;140:291–300. doi: 10.1242/dev.087882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dev.087882</ArticleId>
            <ArticleId IdType="pmc">PMC3597207</ArticleId>
            <ArticleId IdType="pubmed">23221368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miles DC, Wakeling SI, Stringer JM, van den Bergen JA, Wilhelm D, Sinclair AH, Western PS. Signaling through the TGF Beta-Activin receptors ALK4/5/7 regulates testis formation and male germ cell development. PLoS One. 2013;8:1–16. doi: 10.1371/journal.pone.0054606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0054606</ArticleId>
            <ArticleId IdType="pmc">PMC3546992</ArticleId>
            <ArticleId IdType="pubmed">23342175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian-Zhong M, Bi C, Ying Z, Xia J, Cai-Ling P, Yun-Shan Z, Mei-Wen H, Yan-Ru N. Critical role of Emx2 in the pluripotency - differentiation transition in male gonocytes via regulation of FGF9/NODAL pathway. Reproduction. 2016;151:673–681. doi: 10.1530/REP-16-0022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/REP-16-0022</ArticleId>
            <ArticleId IdType="pubmed">27002001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vallier L, Reynolds D, Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol. 2004;275:403–421. doi: 10.1016/j.ydbio.2004.08.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ydbio.2004.08.031</ArticleId>
            <ArticleId IdType="pubmed">15501227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss WA, Taylor SS, Shokat KM. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol. 2007;3:739–744. doi: 10.1038/nchembio1207-739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nchembio1207-739</ArticleId>
            <ArticleId IdType="pmc">PMC2924165</ArticleId>
            <ArticleId IdType="pubmed">18007642</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
